Quality Control of Next-Generation Sequencing-Based HIV-1 Drug Resistance Data in Clinical Laboratory Information Systems Framework.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
14 06 2020
Historique:
received: 13 05 2020
revised: 29 05 2020
accepted: 11 06 2020
entrez: 18 6 2020
pubmed: 18 6 2020
medline: 20 2 2021
Statut: epublish

Résumé

Next-generation sequencing (NGS) in HIV drug resistance (HIVDR) testing has the potential to improve both clinical and public health settings, however it challenges the normal operations of quality management systems to be more flexible due to its complexity, massive data generation, and rapidly evolving protocols. While guidelines for quality management in NGS data have previously been outlined, little guidance has been implemented for NGS-based HIVDR testing. This document summarizes quality control procedures for NGS-based HIVDR testing laboratories using a laboratory information systems (LIS) framework. Here, we focus in particular on the quality control measures applied on the final sequencing product aligned with the recommendations from the World Health Organization HIV Drug Resistance Laboratory Network.

Identifiants

pubmed: 32545906
pii: v12060645
doi: 10.3390/v12060645
pmc: PMC7354600
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Références

Clin Microbiol Infect. 2016 Feb;22(2):191-200
pubmed: 26482266
Front Microbiol. 2018 Sep 13;9:2150
pubmed: 30271393
Sci Rep. 2020 Jan 31;10(1):1634
pubmed: 32005884
Appl Transl Genom. 2016 Jul 01;10:2-9
pubmed: 27668169
Appl Immunohistochem Mol Morphol. 2016 Nov/Dec;24(10):688-694
pubmed: 26469328
Arch Pathol Lab Med. 2013 Aug;137(8):1129-40
pubmed: 23216205
Lancet HIV. 2016 May;3(5):e231-8
pubmed: 27126490
PLoS One. 2020 Feb 26;15(2):e0225352
pubmed: 32102090
J Clin Microbiol. 2016 Dec;54(12):2857-2865
pubmed: 27510831
PLoS Pathog. 2016 May 17;12(5):e1005646
pubmed: 27186986
J Int AIDS Soc. 2014 Nov 02;17(4 Suppl 3):19752
pubmed: 25397497
Virus Res. 2017 Jul 15;239:97-105
pubmed: 27993623
Nat Biotechnol. 2012 Nov;30(11):1033-6
pubmed: 23138292
J Clin Microbiol. 2019 Jul 26;57(8):
pubmed: 31142608
PLoS One. 2013 Jun 28;8(6):e68188
pubmed: 23840830
Lancet HIV. 2018 Nov;5(11):e638-e646
pubmed: 30282603
Nat Med. 2016 Sep;22(9):1043-9
pubmed: 27500724
Nat Rev Dis Primers. 2015 Oct 01;1:15035
pubmed: 27188527
Viruses. 2016 Jan 07;8(1):
pubmed: 26751471
mBio. 2015 Dec 08;6(6):e01888-15
pubmed: 26646014
J Virol Methods. 2017 Feb;240:7-13
pubmed: 27867045
Eur J Clin Microbiol Infect Dis. 2004 Apr;23(4):289-99
pubmed: 15015033
J Infect Dis. 2017 Dec 1;216(suppl_9):S829-S833
pubmed: 28968834
J Infect Dis. 2017 Aug 1;216(3):387-391
pubmed: 28859436
AIDS Behav. 2017 Jan;21(1):27-50
pubmed: 27605364
Top Antivir Med. 2019 Sep/Oct;27(3):111-121
pubmed: 31634862
NPJ Genom Med. 2018 Oct 3;3:28
pubmed: 30302274
Mol Biol Evol. 2018 Mar 1;35(3):719-733
pubmed: 29186559
Clin Chem. 2000 Nov;46(11):1811-7
pubmed: 11067817
BMC Bioinformatics. 2014 Aug 27;15:290
pubmed: 25159034
Clin Chem. 1981 Mar;27(3):493-501
pubmed: 7471403
PLoS One. 2017 Mar 13;12(3):e0173705
pubmed: 28288209
Nucleic Acids Res. 2018 Jul 2;46(W1):W271-W277
pubmed: 29718426
Bioinformatics. 2019 Jun 1;35(12):2029-2035
pubmed: 30407489
Eur J Hum Genet. 2016 Oct;24(10):1515
pubmed: 27628564
J Int AIDS Soc. 2018 Oct;21(10):e25193
pubmed: 30350345
Virus Evol. 2018 May 18;4(1):vey007
pubmed: 29876136
Elife. 2015 Dec 11;4:
pubmed: 26652000
J Clin Microbiol. 2012 Jun;50(6):1936-42
pubmed: 22403431
J Clin Microbiol. 2016 Jun;54(6):1605-1615
pubmed: 27076656
J Infect Dis. 2015 Mar 15;211(6):926-35
pubmed: 25312037
Brief Funct Genomics. 2017 Jul 1;16(4):194-204
pubmed: 27687708
Arch Pathol Lab Med. 2017 Nov;141(11):1544-1557
pubmed: 28782984
Sci Rep. 2019 Jun 20;9(1):8970
pubmed: 31222149

Auteurs

Rupert Capina (R)

National HIV and Retrovirology Laboratories at JC Wilt Infectious Diseases Research Centre, Public Health Agency of Canada, Winnipeg, MB R3E 3L5, Canada.

Katherine Li (K)

National HIV and Retrovirology Laboratories at JC Wilt Infectious Diseases Research Centre, Public Health Agency of Canada, Winnipeg, MB R3E 3L5, Canada.

Levon Kearney (L)

Scientific Informatics Services at National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB R3E 3R2, Canada.

Anne-Mieke Vandamme (AM)

Rega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium.
Center for Global Health and Tropical Medicine, Unidade de Microbiologia, Instituto de Higiene e Medicina Tropical, Universida de Nova de Lisboa, 1349-008 Lisbon, Portugal.

P Richard Harrigan (PR)

Department of Medicine, University of British Columbia, Vancouver, BC V6T 1Z3, Canada.

Kristel Van Laethem (K)

Rega Institute for Medical Research, Department of Microbiology, Immunology and Transplantation, KU Leuven, 3000 Leuven, Belgium.
AIDS Reference Laboratory, University Hospital Leuven, 3000 Leuven, Belgium.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH